07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Amphiregulin (AREG); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); transforming growth factor-b1 (TGFB1) In vitro and mouse studies suggest inhibiting AREG-EGFR1...
07:00 , May 29, 2006 |  BC Week In Review  |  Company News

Alnylam, Bioneer Corp. deal

ALNY granted Bioneer a non-exclusive license to its patents covering siRNAs and their use in mediating RNAi in mammalian cells. The license is for the research products market. Alnylam Pharmaceuticals Inc. (ALNY), Cambridge, Mass.  ...